IL17A and graft versus host disease: In GVHD models, ruxolitinib was shown to decrease the production of chemokines and profibrotic cytokine (Spoerl et al., 2014), and in the neutrophilic asthma mouse model, it decreased the IL-17A level in bronchoalveolar lavage fluid (BALF), reduced the proportion of Th17 cells in lung tissue, and finally reduced airway inflammation.